FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 260 filers reported holding FATE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,360 | -55.5% | 28,000 | 0.0% | 0.01% | -53.8% |
| Q2 2023 | $133,280 | -16.5% | 28,000 | 0.0% | 0.01% | -23.5% |
| Q1 2023 | $159,600 | -43.5% | 28,000 | 0.0% | 0.02% | -45.2% |
| Q4 2022 | $282,520 | -54.9% | 28,000 | 0.0% | 0.03% | -55.7% |
| Q3 2022 | $627,000 | -27.8% | 28,000 | 0.0% | 0.07% | -18.6% |
| Q2 2022 | $869,000 | -20.0% | 28,000 | 0.0% | 0.09% | -15.7% |
| Q1 2022 | $1,086,000 | -10.4% | 28,000 | 0.0% | 0.10% | -6.4% |
| Q4 2021 | $1,212,000 | -29.3% | 28,000 | 0.0% | 0.11% | -28.3% |
| Q3 2021 | $1,715,000 | -29.4% | 28,000 | 0.0% | 0.15% | -37.4% |
| Q2 2021 | $2,430,000 | +5.2% | 28,000 | 0.0% | 0.24% | -6.9% |
| Q1 2021 | $2,309,000 | -9.3% | 28,000 | 0.0% | 0.26% | -22.6% |
| Q4 2020 | $2,546,000 | +138.6% | 28,000 | 0.0% | 0.34% | +106.7% |
| Q3 2020 | $1,067,000 | +3.6% | 28,000 | 0.0% | 0.16% | -6.3% |
| Q2 2020 | $1,030,000 | +65.6% | 28,000 | 0.0% | 0.17% | +1.8% |
| Q1 2020 | $622,000 | – | 28,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |